tbuckley/cabot-search huggingface dataset:
MALARIA IN THE ARMY
Authors: Thomas T. Mackie
Journal: Annals of Internal Medicine (1944)

Article1 April 1944MALARIA IN THE ARMYTHOMAS T. MACKIE, F.A.C.P.THOMAS T. MACKIE, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-20-4-655 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAny effort to evaluate the potential importance of malaria in the army must be based upon consideration of its immediate effects during the war and its more remote effects after demobilization. Its immediate importance lies in possible high morbidity and non-effective rates. Later, returning military and naval personnel may introduce the disease into areas of this country in which malaria has been absent for many years, and augment its incidence and severity in other areas where it is normally endemic. Both of these possibilities imply a relatively high infection rate in military personnel.Comparison of the geographical distribution of the...Bibliography1. KITCHEN SF: The infection of reticulocytes by Plasmodium vivax , Am. Jr. Trop. Med., 1938, xviii, 347-359. CrossrefGoogle Scholar2. KITCHEN SF: The infection of mature and immature erythrocytes by Plasmodium falciparum and Plasmodium malariae , Am. Jr. Trop. Med., 1939, xix, 47-62. CrossrefGoogle Scholar3. TALIAFERRO WH: The cellular basis for immunity in malaria. A symposium on human malaria, 1941, Science Press, Lancaster, Pa., pp. 239-249. Google Scholar4. COGGESHALL LT: Humoral immunity in malaria, Ibid., 250-254. Google Scholar5. CALLENDERGENTZKOW GRCJ: Malaria in the Panama Canal Department United States Army. I. Incidence of primary cases in 1936 and 1937, Mil. Surg., 1936, lxxxiii, 299-316. Google Scholar6. : The Treatment of Malaria. Bulletin of the Health Organization, League of Nations, Geneva, December, 1937. Google Scholar7. CALLENDERGENTZKOW GRCJ: Malaria in the Panama Canal Department United States Army. II. Results of treatment with quinine, atabrine, and plasmochin, Am. Jr. Hyg., 1938, xxviii, 174-189. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: (MRC) U. S. A. Washington, D. C.*Presented before the Regional Meeting of The American College of Physicians, Walter Reed General Hospital, Washington, D. C., April 24, 1942. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCelebrating the ACP Centennial: From the Annals Archive—Malaria Treatment Deputy Editor Deborah Cotton Metrics Cited byCelebrating the ACP Centennial: From the Annals Archive—Malaria TreatmentDeborah Cotton, MD, MPH 1 April 1944Volume 20, Issue 4Page: 655-660KeywordsArmed forcesMalariaMorbidity ePublished: 1 December 2008 Issue Published: 1 April 1944 PDF downloadLoading ...
Lesson of the week: Pulmonary Wegener's granulomatosis misdiagnosed as malignancy
Authors: S Uppal, N Saravanappa, J P Davis, C K T Farmer, D J A Goldsmith
Journal: BMJ (2001)

Cytoplasmic antineutrophil cytoplasmic antibody tests can prevent misdiagnosis of Wegener9s granulomatosis as malignancy
Abstract 969: Lifetime Risk for Sudden Cardiac Death at Selected Index Ages and by Risk Factor Strata and Race: Cardiovascular Lifetime Risk Pooling Project
Authors: Donald M Lloyd-Jones, Jarett D Berry, Hongyan Ning, Xuan Cai, Jeffrey J Goldberger
Journal: Circulation (2009)

Background:  Sudden cardiac death (SCD) is a major public health problem, and it is often the first manifestation of cardiovascular disease. Lifetime risk (LR) for SCD has not been estimated.   Methods:  We used NHLBI public-release datasets from the Framingham Heart Study (FHS), Cardiovascular Health Study (CHS) and Atherosclerosis Risk in Communities (ARIC) Study, which used diverse criteria to define SCD. In FHS, SCD was defined as a coronary death occurring within 1 hour of symptom onset and without other probable cause of death, after extensive review of records and next-of-kin interviews. LR for SCD to age 95 was estimated, with death free of SCD as the competing risk, for men and women at selected ages by risk factor strata and race.   Results:  In the FHS, there were 2261 men and 2733 women followed for a total of 156,036 person-years; during follow up, 374 experienced SCD. At age 40, the overall LRs for SCD were 12.3% (95% CI 10.9 –13.7%) in men and 4.2% (3.4 – 4.9%) in women. Remaining LRs were lower at older index ages (e.g., 5.4% for men and 2.2% for women at age 80). LRs for SCD from age 50 in FHS are shown in the Table, by risk factor strata. Greater individual and aggregate risk factor burden were associated with markedly higher LRs for SCD. Similar associations for risk factors and LR for SCD were observed in ARIC and CHS. In ARIC, LRs for SCD to age 75 were similar to FHS, with greater LRs in black than white men (4.5% vs 2.9%). In CHS, using a more restrictive definition for SCD (within 5 minutes of symptom onset), remaining LRs for SCD at age 65 to age 95 were higher for black than white men (8.7% vs 4.0%).   Conclusions:  These results are the first estimates of lifetime risk for SCD. Established risk factors, male sex, and black race in men are associated with substantially increased lifetime risks for SCD. These relatively high lifetime risks (1 in 8 for men and 1 in 24 for women) should promote public health and individual efforts aimed at preventing this devastating consequence of cardiovascular disease.
Which Variable of Stenosis Severity Best Describes the Significance of an Isolated Left Anterior Descending Coronary Artery Lesion?
Authors: Gian Battista Danzi, Salvatore Pirelli, Luigi Mauri, Roberto Testa, Guglielma R Ciliberto, Daria Massa, Attilio A Lotto, Luigi Campolo, Oberdan Parodi
Journal: Journal of the American College of Cardiology (1998)
Leeches, Spiders, and Astrology: Predilections and Predictions
Authors: T Delbanco
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coronary Endothelial Dysfunction After Kawasaki Disease: Evaluation by Intracoronary Injection of Acetylcholine
Authors: Rumi Yamakawa, Masahiro Ishii, Tetsu Sugimura, Teiji Akagi, Genzyu Eto, Motohumi Iemura, Takahiro Tsutsumi, Hirohisa Kato
Journal: Journal of the American College of Cardiology (1998)
Selection for Treatment in Spina Bifida Cystica
Authors: G. K. Smith, E. D. Smith
Journal: BMJ (1973)

This paper discusses (1) the mortality in 295 patients with myelomeningocele born 1961-9, (2) the “quality of life” of 88 surviving patients born 1961-5, and (3) their implications for selection for treatment in spina bifida cystica. Evidence is presented that high neurological levels, the presence of severe hydrocephalus, especially if present at birth, meningitis and ventriculitis, and gross renal disease are very adverse factors both in mortality and in quality of life. In selection for treatment we recommend immediate repair of the sac in most low lesions, deferring treatment in high lesions, and re-evaluation of the survivors of the latter group at 1 month or later.
Abstract 3872: Identification and characterization of ITGA7 as cancer stem cell marker in esophageal squamous cell carcinoma (ESCC)
Authors: Xiaoyan Ming, Li Fu, Liyi Zhang, Xinyuan Guan
Journal: Cancer Research (2014)

Abstract Cancer stem cells (CSCs) are widely accepted as a specific subpopulation of cells responsible for cancer initiation and progression. CSCs have yet to be identified in ESCC that have an increasing incidence in developed countries. Our recent study in esophageal squamous cell carcinoma (ESCC) has led to the identification of ITGA7 as a functional CSCs marker. ITGA7+ cell population is endowed with stem cell-like properties and high tumorigenic and metastatic potential. ITGA7+ CSCs isolated from ESCC cell lines possessed higher self-renewal activity and were sufficient for tumor initiation, differentiation, and metastasis compared to ITGA7- ESCC cells. Functional studies using lentiviral-based overexpression and suppression systems demonstrated that ITGA7 can promote tumor initiation and metastasis through a deregulated FAK-Raf-MEK1/2-ERK signaling pathway and epithelial-mesenchymal transition. Further characterization of ITGA7+ population may provide a prognostic biomarker for ESCC outcome prediction and a potential therapeutic target. Citation Format: Xiaoyan Ming, Li Fu, Liyi Zhang, Xinyuan Guan. Identification and characterization of ITGA7 as cancer stem cell marker in esophageal squamous cell carcinoma (ESCC). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3872. doi:10.1158/1538-7445.AM2014-3872
Abstract 16730: Prognostic Biomarker for Prediction of Sinus Rhythm Maintenance, Stroke and Long-Term Survival Following Successful Electrical Cardioversion of Non-Valvular Atrial Fibrillation: <i>The Role of Left Atrial Appendage Flow</i>
Authors: Rowlens M Melduni, Jorge Roman, Hon-Chi Lee, Paul A Friedman, Joseph F Malouf, Roger D White, David O Hodge, Nathalie Jean, Charles J Bruce, Thomas M Munger, Bernard J Gersh, Naser M Ammash
Journal: Circulation (2014)

Introduction: Left atrial appendage (LAA) flow depends largely on left ventricular compliance and may play a role in mediating the regulation of left atrial volume-pressure relationships. Hypothesis: We hypothesize that LAA emptying flow velocity (LAAEV) is a predictive factor of long-term outcomes (e.g. recurrent AF, stroke, and survival) after cardioversion for non-valvular AF. Method: We identified 3,251 consecutive patients with non-valvular AF who underwent successful TEE-guided electrical cardioversion (ECV) at our institution between May 2000 and March 2012. Successful ECV was defined as sinus rhythm at time of discharge from the cardioversion unit. Patients were monitored following their ECV procedure for first documentation of recurrent AF, stroke or death. Multivariate Cox proportional hazards models were used to identify independent predictors of long-term outcomes. Patients with &gt;= moderate valvular regurgitation or stenosis were excluded. Results: Among the 3,251 patients who were successfully cardioverted to sinus rhythm, the mean (±SD) LAAEV was 38.43±23 cm/s and the median was 33 cm/s, (interquartile range [IQR], 20-50). Patients with LAAEV &lt;=33 cm/s had higher CHA 2 DS 2 -VASc score (2.6±1.2 vs. 1.9±1.3, P =.009), larger LAVI (52.0±20.9 cc/m 2 vs. 43.3±13.6 cc/m 2 , P &lt;.001) than those with LAAEV &gt;33 cm/s. Pre or post-procedure antiarrhythmic drug use was similar between the two groups. During 1-year follow-up, patients with LAAEV &lt;=33 cm/s had significantly higher rate of AF recurrence than those with LAAEV &gt;33 cm/s (55% vs 45%, P &lt;.001). Likewise, during a mean follow-up of 4.9±3.6 years, similar patterns in 5-year rates were observed for first recurrence of AF (81% vs 73%, P &lt;.001), stroke (7% vs 4%, P =.003) and mortality (31% vs 23%, P &lt;.001) for LAAEV &lt;=33 vs &gt; 33cm/s, respectively. Stepwise multivariate Cox regression analysis revealed that LAAEV &lt;=33 cm/s, age, CHA 2 DS 2 -VASc score were independent predictors of AF recurrence, stroke and mortality. Conclusions: LAA emptying flow velocity is an effective and convenient method for risk stratification of patients undergoing cardioversion for AF. Our data showed that patients with reduced LAAEV have an increased risk for AF recurrence, stroke and death following electrical cardioversion.
Detection of Subclinical Fabry Disease in Patients Presenting With Hypertrophic Cardiomyopathy⁎⁎Editorials published in the Journal of American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Michael J. Ackerman, Andrew P. Landstrom
Journal: Journal of the American College of Cardiology (2007)
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
Authors: Yunching Chen, Rakesh R. Ramjiawan, Thomas Reiberger, Mei R. Ng, Tai Hato, Yuhui Huang, Hiroki Ochiai, Shuji Kitahara, Elizabeth C. Unan, Tejaswini P. Reddy, Christopher Fan, Peigen Huang, Nabeel Bardeesy, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda
Journal: Hepatology (2014)

Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits. Recently, immunotherapy has emerged as a promising treatment strategy, but its role remains unclear in HCCs, which are associated with decreased cytotoxic CD8 + T‐lymphocyte infiltration in both murine and human tumors. Moreover, in mouse models after sorafenib treatment intratumoral hypoxia is increased and may fuel evasive resistance. Using orthotopic HCC models, we now show that increased hypoxia after sorafenib treatment promotes immunosuppression, characterized by increased intratumoral expression of the immune checkpoint inhibitor programmed death ligand‐1 and accumulation of T‐regulatory cells and M2‐type macrophages. We also show that the recruitment of immunosuppressive cells is mediated in part by hypoxia‐induced up‐regulation of stromal cell–derived 1 alpha. Inhibition of the stromal cell–derived 1 alpha receptor (C‐X‐C receptor type 4 or CXCR4) using AMD3100 prevented the polarization toward an immunosuppressive microenvironment after sorafenib treatment, inhibited tumor growth, reduced lung metastasis, and improved survival. However, the combination of AMD3100 and sorafenib did not significantly change cytotoxic CD8 + T‐lymphocyte infiltration into HCC tumors and did not modify their activation status. In separate experiments, antibody blockade of the programmed death ligand‐1 receptor programmed death receptor‐1 (PD‐1) showed antitumor effects in treatment‐naive tumors in orthotopic (grafted and genetically engineered) models of HCC. However, anti‐PD‐1 antibody treatment had additional antitumor activity only when combined with sorafenib and AMD3100 and not when combined with sorafenib alone. Conclusion : Anti‐PD‐1 treatment can boost antitumor immune responses in HCC models; when used in combination with sorafenib, anti‐PD‐1 immunotherapy shows efficacy only with concomitant targeting of the hypoxic and immunosuppressive microenvironment with agents such as CXCR4 inhibitors. (H epatology 2015;61:1591–1602)
Vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: Results of a phase II study
Authors: C. Bauer, M. Dauer, M. Schnurr, K. Jauch, D. Ruettinger, C. Conrad, C. Bruns, B. Emmerich, S. Endres, A. Eigler
Journal: Journal of Clinical Oncology (2008)

3069 Background: Vaccine therapy using dendritic cells can induce antitumor immunity. We report about the final results of a phase II-study using autologous, tumor-lysate pulsed dendritic cells (DC) for the treatment of patients with advanced pancreatic carcinoma. As all patients received concomitant chemotherapy, we investigated systematically the interplay between DC therapy and gemcitabine chemotherapy in a murine pancreatic carcinoma model, correlating the results of ex vivo immuno monitoring tools with clinical efficacy. Methods: Pancreatic carcinoma patients receiving abdominal surgery were recruited to the study. DC therapy was started after recurrence of pancreatic carcinoma or in a primarily palliative situation. Immune response was monitored by ELISPOT and proliferation assays. A pancreatic carcinoma vaccination model was established by transfecting murine pancreatic carcinoma cell line Panc02 with an OVA vector. Mice were vaccinated with bone marrow derived DC loaded with apoptotic Panc02OVA cells, OVA protein or SIINFEKL peptide. Intracellular IFN- γ staining and streptamer staining were used to examine the induction of antigen specific T cells. For tumor induction, Panc02OVA cells were orthotopically injected into C57BL/6 mice. Results: Twelve patients received DC vaccination. Four cases of at least intermittent partial remission or stable disease were seen. These patients had developed strong immunological antitumor responses as demonstrated by DTH skin testing, T cell proliferation assays and ELISPOT assays. Data in the murine model indicate that there is a synergistic clinical efficacy of gemcitabine and DC vaccination therapy despite reduction of specific cytotoxic T cells by concomitant gemcitabine therapy. Results of an in vitro cytotox assay using SIINFEKL-specific, transgene T-cells demonstrate that gemcitabine sensitizes Panc02OVA cells towards T cell mediated lysis. Conclusions: DC vaccination therapy can be of clinical benefit in the setting of advanced pancreatic carcinoma. DC therapy led to immunological responses despite concomitant chemotherapy. Data obtained in a murine model of pancreatic cancer support the concept of a combination of vaccination and chemotherapy. No significant financial relationships to disclose.
Abstract 948: Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia
Authors: Joseph Cherian, Kassoum Nacro, Zhi Ying Poh, Samantha Guo, Melvyn Ho, Haiyan Yang, Sharon Lim, Meng Ling Choong, Jun L. Ding, Joma Kanikadu Joy, Zekui Perlyn Kwek, Boping Liu, Hongqian Esther Ong, Vishal Pendharkar, Anders Poulsen, May Ann Lee, Kanda Sangthongpitag, Charles Chuah, Tiong S. Ong, Jeffrey Hill, Thomas H. Keller, Alex Matter
Journal: Cancer Research (2014)

Abstract Although targeting the BCR-ABL kinase with tyrosine kinase inhibitors (TKI) is effective in chronic phase (CP) CML, targeting BCR-ABL alone is not sufficient to treat late-stage or blast crisis (BC) CML. In BC CML, granulocyte macrophage progenitors (GMPs) acquire the ability to function as leukemic stem cells (LSCs), and are thought to act as a reservoir for TKI resistance. While long-term remission in BC CML is possible with allogeneic stem cell transplantation, only a minority of patients are eligible for transplantation, and may experience high morbidity and mortality. Safe and effective BC CML therapy will likely have to target the BC LSC population to ensure long-term disease control. Recent studies have shown the importance of the MAP kinase interacting serine/threonine kinase (MNK1/2)-eukaryotic translation initiation factor 4E (eIF4E) axis in sustaining BC LSC self renewal. Thus, a single agent which inhibits both BCR-ABL and MNK1/2 kinase simultaneously represents a rational approach to target BC LSCs. Such an agent should be able to distinguish between normal hematopoietic stem cells (HSC) and LSCs. Here, we report the discovery, structure activity relationships, pharmacokinetic properties, and biochemical characteristics of dual MNK1/2 and BCR-ABL inhibitors, ETC-027 and ETC-219. These compounds are able to prevent eIF4E phosphorylation, BCR-ABL-driven growth and proliferation of BC CML cells, as well as inhibit the MNK-eIF4E-dependent self-renewal function of BC LSCs, while leaving normal HSCs untouched. Citation Format: Joseph Cherian, Kassoum Nacro, Zhi Ying Poh, Samantha Guo, Melvyn Ho, Haiyan Yang, Sharon Lim, Meng Ling Choong, Jun Li Ding, Joma Kanikadu Joy, Zekui Perlyn Kwek, Boping Liu, Hongqian Esther Ong, Vishal Pendharkar, Anders Poulsen, May Ann Lee, Kanda Sangthongpitag, Charles Chuah, Tiong S. Ong, Jeffrey Hill, Thomas H. Keller, Alex Matter. Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 948. doi:10.1158/1538-7445.AM2014-948
Dynamic MDCT in the diagnosis of tracheomalacia in cicatricial stenosis of the trachea
Authors: E.A. Chernova, V.V. Chovrin, V.D. Parshin, V.A. Sandricov
Journal: European Respiratory Journal (2013)

Efficiency of surgical treatment of cicatricial stenosis of the trachea and the development of postoperative complications (restenosis) depends, including the presence and severity of tracheomalacia.  PURPOSE. Diagnosis and severity of tracheomalacia in cicatricial stenosis of the trachea, based on changes in the diameter and the thickness of the wall during the forced breathing during dynamic computed tomography (DCT).  MATERIALS AND METHODS. DCT conducted in 30 patients, in 28 verified cicatricial tracheal stenosis in 2 patients - nontracheal thoracic pathologies. Analyzed the assessment criteria for intubation, including wall thickness, type of narrowing of the lumen, the shape of the lumen, the location and extent of tracheomalacia. The greatest diagnostic value of the measurement of the cross-sectional area of the lumen on inspiration and expiration. This percentage was calculated for the collapse of the lumen of the trachea at maximal inspiration, took away the lumen of the trachea at the end of exhalation, divided by the area at a breath, and then multiplied by 100 (Boiselle P. Imaging of the large airways / / Clin Chest Med. 2008. V. 29. P. 181-193).  RESULTS. Tracheomalacia often accompanies cicatricial stenosis of the trachea. Percentage wears off trachea ≥ 50%, as the current diagnostic criteria, accepted as having tracheomalacia. In our study in 21 of 30 patients determined collapse of the lumen of the trachea, which is greater than the data traheobronchoskopy, in 3 out of 30.  CONCLUSIONS. Dynamic MDCT is a promising method in the diagnosis of tracheomalacia in cicatricial stenosis of the trachea and can play an important role in the choice of surgical treatment.
Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era
Authors: Niklas Gunnarsson, Stenke Leif, Martin Höglund, Fredrik Sandin, Magnus Björkholm, Arta Dreimane, Mats Lambe, Berit Markevärn, Ulla Olsson-Strömberg, Johan Richter, Hans Wadenvik, Jonas Wallvik, Anders Själander
Journal: Blood (2014)